Exagen Inc. XGN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Exagen Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exagen Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exagen Inc.'s cash & equivalents?
- Exagen Inc. (XGN) reported cash & equivalents of $21.71M in Q1 2026.
- How has Exagen Inc.'s cash & equivalents changed year-over-year?
- Exagen Inc.'s cash & equivalents increased by 90.6% year-over-year, from $11.39M to $21.71M.
- What is the long-term trend for Exagen Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Exagen Inc.'s cash & equivalents has grown at a -10.8% compound annual growth rate (CAGR), from $57.55M to $32.42M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.